What is QuaDPharma?
QuaDPharma Inc operates as a specialized entity within the pharmaceutical sector, maintaining a lean operational structure with a workforce of 10 to 19 professionals. Despite its compact size, the company generates annual revenue in the range of 10M to 25M, demonstrating high efficiency and a strong value proposition in its niche. The firm focuses on pharmaceutical development, utilizing its resources to navigate the complex regulatory and research-intensive requirements of the life sciences industry. Its ability to attract institutional capital highlights its potential for sustained growth and innovation in drug development and therapeutic solutions.
How much funding has QuaDPharma raised?
QuaDPharma has raised a total of $1.5M across 2 funding rounds:
Other Financing Round
$500K
Other Financing Round
$1M
Other Financing Round (2012): $500K with participation from Rand
Other Financing Round (2012): $1M led by Rand Capital SBIC , Inc. and Advantage Capital
Key Investors in QuaDPharma
Rand
RAND Corporation is a nonprofit research organization that develops solutions to public policy challenges, often providing analytical support for complex industry sectors.
Rand Capital SBIC , Inc.
A business development company that provides capital and managerial assistance to small and medium-sized enterprises to foster long-term growth.
Advantage Capital
A venture capital firm specializing in diverse sectors including life sciences, cleantech, and information technology, with a focus on driving regional economic development.
What's next for QuaDPharma?
With this major enterprise-level funding, QuaDPharma is poised to transition into a more aggressive growth phase. The strategic allocation of these funds will likely prioritize the expansion of research and development capabilities, potentially shortening the time-to-market for its pipeline assets. Furthermore, the involvement of seasoned institutional backers suggests a focus on scaling operational infrastructure and enhancing market penetration. As the company matures, the emphasis will likely shift toward optimizing its commercialization strategies and exploring new therapeutic frontiers, ensuring that the firm remains a resilient player in the global pharmaceutical market.
See full QuaDPharma company page
